Literature DB >> 872876

Effects of 5HT uptake inhibitors on the pressor response to 5HT in the pithed rat. The significance of the 5HT blocking property.

E N Petersen, S O Olsson, R F Squires.   

Abstract

A study was made of the effects of several serotonin (5HT) uptake inhibitors on 5HT-induced pressor responses in pithed rats, 5HT uptake into rat brain synaptosomes and 5HT-induced contractions of rat ileum in vitro. All drugs except desimipramine were potent uptake inhibitors (IC50 less than 10(-7) M), Femoxetine, chlorimipramine, imipramine and desimipramine all inhibited 5HY-induced contractions of the rat ileum in vitro and the pressor response to 5HT in vivo. FG 7051, FG 7052 and dexchlorpheniramine were weak 5HT antagonists on the rat ileum but potentiated the pressor responses to 5HT; the most potent uptake inhibitor, FG 7051, was the strongest potentiator. These results suggest that uptake inhibition is important for this potentiation. It is concluded that 5HT uptake inhibitors with potent 5HT receptor blocking properties antagonize the pressor response to 5HT and mask the potentiation due to uptake inhibition.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 872876     DOI: 10.1016/0014-2999(77)90019-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  16 in total

Review 1.  The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression.

Authors:  Eleni Pitsillou; Sarah M Bresnehan; Evan A Kagarakis; Stevano J Wijoyo; Julia Liang; Andrew Hung; Tom C Karagiannis
Journal:  Mol Biol Rep       Date:  2019-10-14       Impact factor: 2.316

2.  Evidence for a dopaminergic dominance in the 4,alpha-dimethyl-m-tyramine-induced hypermotility in mice.

Authors:  C Rüdeberg
Journal:  Psychopharmacology (Berl)       Date:  1978-12-08       Impact factor: 4.530

3.  EEG and blood level of the potential antidepressant paroxetine after a single oral dose to normal volunteers.

Authors:  G R McClelland; P Raptopoulos
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

4.  Acute or chronic changes of noradrenergic transmission do not affect the alpha-adrenoceptor-mediated inhibition of 3H-serotonin release in the cerebral cortex.

Authors:  E Schlicker; M Göthert; R Clausing
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-07       Impact factor: 3.000

5.  Serotonin-receptor-mediated modulation of Ca2+-dependent 5-hydroxytryptamine release from neurones of the rat brain cortex.

Authors:  M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-11       Impact factor: 3.000

6.  Extracellular 5-hydroxytryptamine inhibits 5-hydroxytryptamine release from rat brain cortex slices.

Authors:  M Göthert; G Weinheimer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-12       Impact factor: 3.000

7.  Alpha-adrenoceptor-mediated modulation of 5-hydroxytryptamine release from rat brain cortex slices.

Authors:  M Göthert; H Huth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-08       Impact factor: 3.000

8.  Evidence for common pharmacological properties of [3H]5-hydroxytryptamine binding sites, presynaptic 5-hydroxytryptamine autoreceptors in CNS and inhibitory presynaptic 5-hydroxytryptamine receptors on sympathetic nerves.

Authors:  G Engel; M Göthert; E Müller-Schweinitzer; E Schlicker; L Sistonen; P A Stadler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-09       Impact factor: 3.000

9.  Is Ro 11-2465 (cyan-imipramine) an antagonist of postsynaptic serotonin receptors?

Authors:  L Pawłowski; H Kwiatek; Z Górka
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

10.  Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites.

Authors:  G Engel; M Göthert; D Hoyer; E Schlicker; K Hillenbrand
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-01       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.